NASDAQ:CVRX CVRx (CVRX) Stock Price, News & Analysis $8.10 -0.26 (-3.11%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About CVRx Stock (NASDAQ:CVRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CVRx alerts:Sign Up Key Stats Today's Range$8.04▼$8.8650-Day Range$6.95▼$10.0052-Week Range$6.40▼$33.13Volume258,177 shsAverage Volume256,335 shsMarket Capitalization$174.93 millionP/E RatioN/ADividend YieldN/APrice Target$13.67Consensus RatingModerate Buy Company OverviewCVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Read More… $5k to $1.3m in just 3 trades (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. CVRx Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks56th Percentile Overall ScoreCVRX MarketRank™: CVRx scored higher than 56% of companies evaluated by MarketBeat, and ranked 502nd out of 1,013 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingCVRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCVRx has only been the subject of 4 research reports in the past 90 days.Read more about CVRx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CVRx are expected to grow in the coming year, from ($2.56) to ($2.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CVRx is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CVRx is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCVRx has a P/B Ratio of 2.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CVRx's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.45% of the float of CVRx has been sold short.Short Interest Ratio / Days to CoverCVRx has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in CVRx has recently decreased by 1.49%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCVRx does not currently pay a dividend.Dividend GrowthCVRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted16.45% of the float of CVRx has been sold short.Short Interest Ratio / Days to CoverCVRx has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in CVRx has recently decreased by 1.49%, indicating that investor sentiment is improving. News and Social Media1.3 / 5News Sentiment0.37 News SentimentCVRx has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for CVRx this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for CVRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, CVRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $322,545.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders18.90% of the stock of CVRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.27% of the stock of CVRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CVRx's insider trading history. Receive CVRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CVRx and its competitors with MarketBeat's FREE daily newsletter. Email Address CVRX Stock News HeadlinesCVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024October 15 at 4:30 PM | globenewswire.comLake Street Reaffirms Their Buy Rating on Artivion (AORT)October 11, 2024 | markets.businessinsider.comTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…October 17, 2024 | Timothy Sykes (Ad)Craig-Hallum Sticks to Its Buy Rating for MiMedx Group (MDXG)October 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Certara (CERT) and CVRx (CVRX)October 7, 2024 | markets.businessinsider.comCVRx (CVRX) Gets a Buy from Craig-HallumOctober 3, 2024 | markets.businessinsider.comTarget CEO Brian Cornell nearing last year at retailer's helmSeptember 26, 2024 | bizjournals.comCVRX Sep 2024 7.500 call (CVRX240920C00007500)September 19, 2024 | sg.finance.yahoo.comSee More Headlines CVRX Stock Analysis - Frequently Asked Questions How have CVRX shares performed this year? CVRx's stock was trading at $31.44 at the start of the year. Since then, CVRX shares have decreased by 74.2% and is now trading at $8.10. View the best growth stocks for 2024 here. How were CVRx's earnings last quarter? CVRx, Inc. (NASDAQ:CVRX) released its quarterly earnings results on Monday, July, 29th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.14. The company earned $11.81 million during the quarter, compared to the consensus estimate of $11.84 million. CVRx had a negative trailing twelve-month return on equity of 77.62% and a negative net margin of 122.52%. When did CVRx IPO? CVRx (CVRX) raised $100 million in an initial public offering (IPO) on Wednesday, June 30th 2021. The company issued 6,250,000 shares at a price of $15.00-$17.00 per share. Who are CVRx's major shareholders? Top institutional investors of CVRx include SG Americas Securities LLC (0.06%). Insiders that own company stock include & Johnson Johnson, Kirk G Nielsen, Joseph P Slattery, Kevin Hykes, Paul Verrastro and Mudit K Jain. View institutional ownership trends. How do I buy shares of CVRx? Shares of CVRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CVRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that CVRx investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Visa (V). Company Calendar Last Earnings7/29/2024Today10/17/2024Next Earnings (Confirmed)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Devices Sub-IndustryMedical Equipment Current SymbolNASDAQ:CVRX CUSIPN/A CIK1235912 Webwww.cvrx.com Phone763-416-2840Fax763-416-2841Employees200Year FoundedN/APrice Target and Rating Average Stock Price Target$13.67 High Stock Price Target$15.00 Low Stock Price Target$12.00 Potential Upside/Downside+68.7%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,200,000.00 Net Margins-122.52% Pretax Margin-122.16% Return on Equity-77.62% Return on Assets-51.34% Debt Debt-to-Equity Ratio0.53 Current Ratio10.08 Quick Ratio8.85 Sales & Book Value Annual Sales$44.39 million Price / Sales3.94 Cash FlowN/A Price / Cash FlowN/A Book Value$3.65 per share Price / Book2.22Miscellaneous Outstanding Shares21,596,000Free Float17,668,000Market Cap$174.93 million OptionableOptionable Beta1.26 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report This page (NASDAQ:CVRX) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CVRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CVRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
